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Abstract
Background: Little is known about factors that determine health status decline in clinical trials of COPD.
Objectives: To examine health status changes over 3 years in the TORCH study of salmeterol+fluticasone
propionate (SFC) vs. salmeterol alone, fluticasone propionate alone or placebo.
Methods: St George’s Respiratory Questionnaire (SGRQ) was administered at baseline then every 6 months.
Measurements and Main Results: Data from 4951 patients in 28 countries were available. SFC produced
significant improvements over placebo in all three SGRQ domains during the study: (Symptoms -3.6 [95% CI -4.8,
-2.4], Activity -2.8 [95% CI -3.9, -1.6], Impacts -3.2 [95% CI -4.3, -2.1]) but the pattern of change over time differed
between domains. SGRQ deteriorated faster in patients with Global Initiative for Chronic Obstructive Lung Disease
(GOLD) stages III & IV relative to GOLD stage II (p < 0.001). There was no difference in the relationship between
deterioration in SGRQ Total score and forced expiratory volume in one second (FEV1) decline (as % predicted) in
men and women. Significantly faster deterioration in Total score relative to FEV1 % predicted was seen in older
patients (≥ 65 years) and there was an age-related change in Total score that was independent of change in FEV1.
The relationship between deterioration in FEV1 and SGRQ did not differ in different world regions, but patients in
Asia-Pacific showed a large improvement in score that was unrelated to FEV1 change.
Conclusions: In addition to treatment effects, health status changes in clinical trials may be influenced by
demographic and disease-related factors. Deterioration in health status appears to be fastest in older persons and
those with severe airflow limitation.
Trial Registration: ClinicalTrials.gov: NCT00268216
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Background
The ability to reliably measure health status (sometimes
referred to as health-related quality of life) by adminis-
tering standardized questionnaires has greatly expanded
our understanding of the effects of chronic respiratory
diseases like chronic obstructive pulmonary disease
(COPD) [1]. Disease-specific questionnaires like the St
George’s Respiratory Questionnaire (SGRQ) reflect a
wide range of different health impacts in COPD [1], are
designed to provide an overall measure of impairment,
and are now used widely in randomized controlled trials
in COPD. A number of relatively small longitudinal
observational studies [2-5] have shown that a decline in
health status may be seen over time, but there have
been relatively few studies of long-term treatment effects
on health status decline. The first of these was the
Inhaled Steroids in Obstructive Lung Disease (ISOLDE)
study, which showed that health status measured using
the SGRQ deteriorated progressively over 3 years [6], an
effect that was slowed by the inhaled corticosteroid
(ICS) fluticasone propionate (FP) [7,8]. The recent 3-
year Towards a Revolution in COPD Health (TORCH)
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and 4-year Understanding Potential Long-term Impacts
on Function with Tiotropium (UPLIFT) studies have
both reported health status gains that lasted the entire
duration of the study [9,10]. In view of the pivotal nat-
ure of these studies, it is important to understand the
nature of these improvements and factors that may
influence them. We have used data from the TORCH
trial to explore these factors.
TORCH was a double-blind placebo-controlled rando-
mized parallel group study to investigate the benefits of
FP and the long-acting beta2 agonist salmeterol (SAL)
combined in one inhaler (SAL + FP [SFC]) vs. placebo
[9]. Patients were recruited from 42 countries. The pri-
mary endpoint was all-cause mortality at 3 years, mea-
sured in the intention-to-treat (ITT) population. Health
status, measured using the SGRQ, was a pre-specified
secondary endpoint. The results obtained with the total
SGRQ score have been reported [9]. In this analysis, we
provide data about the effect of therapy on the SGRQ
domains, and an analysis of demographic and disease-
related factors that may influence long-term changes in
health status.
Methods
Details of the TORCH study design and analysis plan
have been published previously [11]. The study was
approved by local ethics review committees and con-
ducted in accordance with the Declaration of Helsinki
and Good Clinical Practice guidelines. All patients gave
written informed consent. Methods pertaining specifi-
cally to the current analysis will be described here.
Patients
The population for this study (the ‘health outcomes
population’) was a subset of the total efficacy popula-
tion. It consisted of patients for whom SGRQ question-
naire translations were determined to be linguistically
and culturally valid, could potentially have a total SGRQ
score calculated, and had completed at least one ques-
tionnaire during the study. Suitable translations were
not available for five languages at the start of the study.
Furthermore, where translations were available, during
the years from study inception to conclusion the stan-
dards required for linguistic validity had evolved. We
wished to ensure that all translations met current stan-
dards, so prior to breaking the treatment code, and
independently of the sponsor, each country-language
combination went through a process of two back trans-
lations, pilot testing in COPD patients and developer
review. Based on this, one of three actions was taken:
• country-language combination was judged valid (n = 28)
• country-language combination was valid after devel-
oper-agreed modification of the scoring algorithm:
◦ if there were ≤ 2 poorly translated items that could
be removed (n = 4)
◦ incorrect response ordering that could be corrected
when scoring (n = 1)
• country-language combination was excluded - failed
to meet current standards (n = 4).
For the analysis of the relationship between the
change in forced expiratory volume in one second
(FEV1) and the change in SGRQ, only patients with
measurements of both endpoints during treatment and
at the same timepoint were included. Therefore this is a
subset of the general health outcomes population.
Statistical analyses
Missed SGRQ items were handled according to the devel-
opers’ instructions in the SGRQ manual. Scores were ana-
lyzed as change from baseline using mixed model repeated
measures (MMRM) including treatment, smoking status,
age, gender, baseline FEV1, body mass index (BMI), region,
visit, treatment by visit, baseline SGRQ score, and visit by
baseline SGRQ. Estimated treatment differences at each
visit were averaged with equal weights to obtain the overall
treatment effect over the study period.
The impact of the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stage on change in
SGRQ score from baseline was assessed using MMRM
analysis of the placebo arm employing identical covari-
ates, except that the GOLD stage was incorporated into
the model and treatment was not.
The impact of demographic factors on the relationship
between change in SGRQ and change in FEV1 over 3
years was tested using analysis of covariance, with and
without adjustment for baseline covariates. All treatment
arms were combined for this analysis; because of its
exploratory nature, significance was accepted at p <
0.01. We tested both the slope of this relationship and
the intercept, this being the change in SGRQ associated
with no change in FEV1.
Results
Of the 6112 patients that formed the primary efficacy
population, 4951 provided SGRQ data that met the cri-
teria for inclusion in the health outcomes population in
28 of 42 countries that participated in TORCH. Patients
were allocated to one of five regions that had been pre-
specified (see Additional file 1 for details). Baseline
demographics by treatment group are presented in
table 1, along with corresponding data from the patients
in the ITT population [9]. Baseline variables were very
similar across treatment groups and between the health
outcomes and ITT populations. Differences between the
two study populations in terms of proportion of patients
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recruited from different regions were due to the absence
of suitably validated questionnaires for some languages
in Asia-Pacific and Eastern Europe.
More patients withdrew in the placebo arm than those
receiving active treatment. By the end of 3 years, 45% of
placebo-treated patients in this analysis had withdrawn
compared with salmeterol 39%, FP 40% and SFC 35%.
SGRQ change from baseline
SGRQ scores by visit for the total and the domain scores
are shown in Figure 1. The pattern of change in the pla-
cebo arm differed between domains: the improvement in
Symptoms score over the first 6 months was sustained for
the rest of the study; there was a small improvement in
the Activity score over the first 6 months, thereafter it
deteriorated; the Impacts domain showed an initial small
improvement, followed by deterioration. Within domains,
the pattern of change was similar in all treatment arms,
but the magnitude differed. Averaged over the 3-year per-
iod, SFC was superior to placebo in all domains (all p <
0.001): Symptoms -3.6 (95% CI -4.8 to -2.4), Activity -2.8
(95% CI -3.9 to -1.6), Impacts -3.2 (95% CI -4.3 to -2.1).
Salmeterol and FP showed an intermediate response. SFC
was also superior to salmeterol (all domains p ≤ 0.001)
and FP (all domains p < 0.05).
Effect of region on SGRQ changes
There were considerable regional variations in change in
total SGRQ score (Figure 2). After 3 years, placebo-
treated patients who completed the study were worse
than at baseline in three regions, the USA, Western Eur-
ope and other, unchanged in Eastern Europe, and
improved in Asia-Pacific. Numerically, patients receiving
SFC improved in all regions except the USA. However,
the actual treatment differences between SFC and pla-
cebo were fairly consistent, ranging from 1.8 to 5.0 at 3
years. A test for interaction between region and treat-
ment effect was not significant (p = 0.16).
SGRQ by GOLD stage
Baseline SGRQ scores in TORCH patients grouped by
GOLD stage have been reported: GOLD stage II, 45.4 ±
17.7 (SD); GOLD stage III, 50.0 ± 16.5; GOLD stage IV,
56.5 ± 15.0 [12]. The differences between GOLD stage
were clinically and statistically significant (p < 0.05), but
within each stage patients exhibited a wide range in
SGRQ score. Using MMRM analysis of change from
baseline, the change over 3 years in patients treated
with placebo was very different between GOLD stages
(Figure 3). Patients in GOLD stage II who received pla-
cebo showed an overall improvement, while those in
GOLD stages III and IV deteriorated. Changes with
treatment have been reported elsewhere [12].
Relationship between change in FEV1 and change in
SGRQ score
For this analysis, data from all treatment arms were
combined (3913 evaluable patients). In patients who
Table 1 Demographic and baseline characteristics of health outcomes population and all randomized patients
(efficacy population)
Variable Placebo
(n = 1231)
SAL
(n = 1232)
FP
(n = 1248)
SFC
(n = 1240)
Total HO population
(n = 4951)
Total population
(n = 6112)
Age at enrollment (years) 65.0 (8.2) 65.2 (8.2) 65.0 (8.5) 65.0 (8.3) 65.1 (8.3) 65.0 (8.3)
Male gender (%) 921 (75) 926 (75) 923 (74) 912 (74) 3682 (74) 4631 (76)
BMI (kg/m2) 25.8 (5.2) 25.7 (5.1) 25.6 (5.2) 25.6 (5.3) 25.7 (5.2) 25.4 (5.18)
Geographical region (%)
USA 342 (27.8) 344 (27.9) 348 (27.9) 345 (27.8) 1379 (27.9) 1388 (22.7)
Asia-Pacific 89 (7.2) 93 (7.5) 95 (7.6) 93 (7.5) 370 (7.5) 758 (12.4)
Eastern Europe 185 (15) 186 (15.1) 185 (14.8) 184 (14.8) 740 (14.9) 1154 (18.9)
Western Europe 410 (33.3) 405 (32.9) 413 (33.1) 409 (33) 1637 (33.1) 1908 (31.2)
Other 205 (16.7) 204 (16.6) 207 (16.6) 209 (16.9) 825 (16.7) 935 (15.3)
Current smoker (%) 538 (44) 536 (44) 543 (44) 539 (43) 2156 (44) 2630 (43)
Pack-years smoked 49.5 (27.5) 50.6 (28.6) 50.0 (28.8) 47.7 (26.6) 49.4 (27.9) 48.5 (27.4)
Post-bronchodilator FEV1 (l)* 1.24 (0.42) 1.21 (0.40) 1.22 (0.42) 1.24 (0.43) 1.23 (0.42) 1.22 (0.42)
Post-bronchodilator FEV1 (% predicted*) 44.5 (12.3) 43.7 (12.4) 44.3 (12.3) 44.6 (12.3) 44.3 (12.3) 44.0 (12.4)
Reversibility (% predicted FEV1)* 3.7 (3.8) 3.7 (4.0) 3.6 (3.7) 3.7 (3.6) 3.7 (3.8) 3.7 (3.7)
Pre-bronchodilator FEV1/FVC ratio* 48.4 (11.0) 48.6 (11.0) 48.1 (10.8) 48.1 (10.8) 48.3 (10.9) 48.6 (10.8)
Baseline SGRQ total score 49.0 (17.4) 49.9 (16.6) 49.5 (17.1) 48.9 (17.4) 49.3 (17.1) -
Data are mean (standard deviation) unless otherwise indicated
*Data are from visit one (screening)
BMI = body mass index; FP = fluticasone propionate; FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; HO = health outcomes; SAL =
salmeterol; SFC = salmeterol+fluticasone propionate; SGRQ = St George’s Respiratory Questionnaire
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withdrew early, the last value carried forward was used
for both SGRQ and FEV1 data. The change in SGRQ at
3 years correlated significantly with change in FEV1: r =
-0.24, p < 0.0001 (all treatment arms combined). In the
regression between ΔSGRQ (dependent variable) and
ΔFEV1 (independent variable), the intercept value
for the SGRQ (i.e. the mean change in SGRQ that
was associated with zero change in FEV1) was -0.7 units,
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Figure 1 Plots showing adjusted mean change for the SGRQ Total score (A) and the Symptoms (B), Activity (C) and Impacts (D)
domains, over 3 years by treatment group. A lower score indicates better health. The plot for each domain shows the change over time as
the left-hand panel (error bars are standard error). The right-hand plots are from a repeated measures analysis of the effects of treatment over
the 3 years of the study and are pair-wise comparisons between the treatment arms (error bars are 95% confidence intervals).
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p = 0.003. This indicates that the SGRQ score improved
slightly overall, even in the absence of a change in FEV1.
Further analyses were performed to test for the influ-
ence of age, gender and region on the slope of this rela-
tionship and its intercept. When tested using FEV1
expressed in millilitres, women had a greater change in
SGRQ score for a given change in FEV1 (p = 0.007), but
this effect on the slope disappeared when change in
FEV1 was expressed as percentage predicted (p = 0.7).
To test for effects of age, patients were divided into
cohorts: < 55, 55 to 64, 65 to 74 and ≥ 75 years. In a
univariate model, there was no significant effect on the
slope (p = 0.027), but the intercepts did differ (p <
0.0001): < 55 years, -2.4 units; 55-64 years, -1.6 units; 65
to 74 years, 0.0 units; ≥ 75 years, +0.8 units, suggesting
that in younger patients, SGRQ tended to improve, even
in the absence of a change in FEV1.
In a multivariate model that adjusted for effects of sex,
region, BMI, smoking status, baseline SGRQ, baseline
FEV1 (as percentage predicted) and exacerbations in the
previous year, age had an influence on both the slopes
(p = 0.008) and intercepts (p < 0.0001) of the relation-
ship between deterioration in SGRQ and decline in
FEV1 (Figure 4). In this analysis, the intercepts were -1.9
units (<55 years), -1.7 units (55 to 64 years), -0.3 units
(65 to 74 years) and +1.1 units (≥ 75 years). Older
patients had a greater deterioration in SGRQ relative to
the change in FEV1 than did patients < 64 years.
Region had no effect on the slope of the relationship
between change in SGRQ and change in FEV1 (p >
0.05), but influenced the intercept (p < 0.0001): Asia-
Pacific, -5.1 units; other, -1.2 units; Eastern Europe, -0.7
units; Western Europe, 0.0 units; USA, 0.1 units. No
other covariate had a significant effect on this relation-
ship in the univariate models.
SGRQ and exacerbation rate
Data from all treatment arms were combined for this
analysis. The change in SGRQ during the study was sig-
nificantly related to exacerbation rate recorded during
the study. In patients with no exacerbations, the SGRQ
improved: -2.6 (95% CI -3.5 to -1.7) units/year; in
patients with a low exacerbation rate (> 0 and ≤ 1 per
year), there was a small overall improvement: -0.9 (95%
CI -1.6 to -0.1) units/year; in patients with > 1 exacerba-
tion per year, the SGRQ deteriorated: 2.8 (95% CI 2.1 to
3.6) units/year.
Early withdrawal and SGRQ
There was a clear effect of both baseline SGRQ and rate
of deterioration during the study on the likelihood of
early withdrawal (Figure 5). Patients who entered the
study with better health (average baseline score < 50) or
did not deteriorate above this level, were more likely to
remain in the study for more than 30 months. Drop-
outs in the placebo arm up to week 156 varied across
regions: Asia-Pacific 28%; Eastern Europe 35%, Western
Europe 46%; other 50%; the USA 52%.
Discussion
This study provides new insights into factors that deter-
mine health status decline and issues that must be con-
sidered in multinational studies that include health
status as an outcome. There were improvements in all
SGRQ domains with all active treatments, but SFC had
the greatest effect. Interestingly, the pattern of change in
score differed between domains. The Activity and
Impact scores behaved similarly to those reported in
ISOLDE, another 3-year study [8] but the behaviour of
the Symptoms domain was clearly different because the
Figure 4 Relationship between change in SGRQ Total score
over the 3-year study period and change in FEV1 by age
category. A negative score indicates improved health. Using
analysis of covariance: difference in slopes p = 0.008; difference in
intercepts p < 0.0001.
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Figure 5 Change in SGRQ Total score in patients treated with
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initial improvement was maintained for the rest of the
study with no apparent deterioration. A similar pattern
has been reported with the SGRQ symptoms score in
the 3-year Bronchitis Randomized on NAC Cost-Utility
Study (BRONCUS) trial of n-acetyl cysteine [13]. One
possible explanation may be the large and prolonged
effect of a single exacerbation on SGRQ score, particu-
larly the Symptoms domain, which may continue for
over 3 months [14]. In TORCH, patients were excluded
only if they had an exacerbation requiring treatment
during the 2-week run-in period, so the sustained
improvement seen in this domain may have occurred if
some patients had an exacerbation in the weeks before
run-in. In BRONCUS, exacerbations prior to randomiza-
tion were not an exclusion criterion. By contrast, in
ISOLDE, the patients had a 6-week run-in period and
were then given a 2-week course of prednisolone, so
effects of any prior exacerbations would have been
minimized.
Our exploratory subgroup analyses provide observa-
tions that generate new hypotheses about health status
decline in COPD. The rate of deterioration in men and
women relative to loss of FEV1 appeared to be the same
once gender differences in the absolute value of FEV1
were taken into account. Patients with severe and very
severe airway obstruction at baseline showed significant
deterioration in their health status over 3 years, whereas
those with moderate obstruction improved. One possible
explanation for this difference is the effect of exacerba-
tions on SGRQ scores [15,16], and the known relation-
ship between FEV1 and exacerbation rates [13,14,17]. In
TORCH, patients with no exacerbations showed a mean
improvement in Total SGRQ score over 3 years,
whereas those with > 1 exacerbation per year had a sig-
nificant worsening of health. A link between SGRQ
deterioration and exacerbation rate was reported in ISO-
LDE, and statistical modelling of those data suggested a
causal relationship between a lower rate of exacerba-
tions in patients with FP and a slower rate of worsening
of SGRQ [16]. These observations from ISOLDE and
TORCH suggest that recurrent exacerbations have a
cumulative effect on health status similar to that
reported for FEV1 [18,19].
Older people appeared to have a faster loss of health
status than younger people. This was seen after other
demographic and disease-related effects such as gender
and baseline FEV1 had been taken into account, suggest-
ing that health status deterioration in COPD may accel-
erate with age. This may be related to increasing
comorbidity, but another factor may be an age-related
increase in frailty and self-reported functional decline,
rather than a specific chronic disease effect [20].
There appears to have been a ‘trial effect’ in Asia-Paci-
fic, where sustained improvements in SGRQ score were
seen irrespective of whether patients received active
study treatment. One plausible explanation for this is
that patients’ health in that region, particularly China,
may have improved because they received better health-
care by joining a clinical trial (JP Zheng, personal com-
munication). China contributed 65% of the Asia-Pacific
patients and a similar SGRQ improvement has been
reported in the placebo limb of two large studies from
that country [21,22], although this was not seen in a
third [23]. One of the studies compared SFC with pla-
cebo and the active treatment produced a significantly
greater effect on SGRQ despite a large effect on placebo
[22]. In TORCH, the relationship between deterioration
in SGRQ and decline in FEV1 in Asia-Pacific was not
different from that seen in the other regions. Taken
together, these observations suggest that the SGRQ does
measure treatment effects and disease progression in
China and Asia-Pacific in a similar way to other coun-
tries. However, such instruments also appear to detect
health status gains that may occur on recruitment to a
clinical trial in developing health economies. In this
context, it should be noted that the withdrawal rate in
the USA was 56% compared with 29% in Asia-Pacific.
TORCH extends the observations reported in other
studies that patients with poor health at baseline and
those that deteriorated faster were more likely to with-
draw earlier than others [8,24]. In TORCH, the only
patients who remained in the study for more than 30
months were those in whom there had, on average,
been no deterioration in health status compared with
baseline. This suggests that patients and their physicians
expect the patient’s health to improve on entering a
study of this kind, and any deterioration may lead to
early withdrawal. This will lead to a ‘healthy survivor’
effect as many of the sickest people withdraw. That
effect becomes especially important when there is differ-
ential drop-out between treatment arms, as in this study
where there was a 10% absolute and 20% relative differ-
ence in drop-out rate between the placebo and SFC
arms. This ‘informative drop-out’ process may lead to a
biased estimate of treatment efficacy, in this case an
underestimate. Health status measurements now form
an established assessment of treatment efficacy in
COPD because they are a marker of an important clini-
cal outcome (health-related quality of life) and are
poorly correlated with FEV1. The observations made
here were obtained with the SGRQ but are likely to be
seen with any validated health status measure in COPD,
as a comparison between the SGRQ and a new instru-
ment with a very different structure showed that the
two questionnaires appear to be highly correlated and
behave in a very similar way [25]. This analysis suggests
that studies with a low baseline exacerbation frequency,
different drop-out rates, and large Eastern Europe and
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Asia-Pacific region participation may not give the same
results as those involving participants in Western Eur-
ope and the USA.
Additional material
Additional file 1: The number of patients with at least one valid
SGRQ in which a total score could be calculated completed in each
country. Lists the number of patients with at least one valid SGRQ in
which a total score could be calculated completed in each country.
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